Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation approaches. Few biological factors at diagnosi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Natalia Estrada, Blanca Xicoy, Fabian Beier, Olga Garcia, Cristian Morales, Concepción Boqué, Miguel Sagüés, Mónica S. Ventura Ferreira, Rolando Vallansot, Sílvia Marcé, Marta Cabezón, Tim H. Brümmendorf, Lurdes Zamora
Formato: article
Lenguaje:EN
Publicado: Wolters Kluwer 2021
Materias:
Acceso en línea:https://doaj.org/article/eed0d7528f1d408cb71f85ec9f094861
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:eed0d7528f1d408cb71f85ec9f094861
record_format dspace
spelling oai:doaj.org-article:eed0d7528f1d408cb71f85ec9f0948612021-11-25T07:58:36ZInfluence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients2572-924110.1097/HS9.0000000000000657https://doaj.org/article/eed0d7528f1d408cb71f85ec9f0948612021-12-01T00:00:00Zhttp://journals.lww.com/10.1097/HS9.0000000000000657https://doaj.org/toc/2572-9241Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation approaches. Few biological factors at diagnosis have been associated with this level of response. Telomere length (TL) in peripheral blood cells of patients with CML has been related to disease stage, response to therapy and disease progression, but little is known about its role on DMR. In this study, we analyzed if age-adjusted TL (referred as “delta-TL”) at diagnosis of chronic phase (CP)-CML might correlate with the achievement of DMR under first-line imatinib treatment. TL from 96 CP-CML patients had been retrospectively analyzed at diagnosis by monochrome multiplex quantitative PCR. We observed that patients with longer age-adjusted telomeres at diagnosis had higher probabilities to achieve DMR with imatinib than those with shortened telomeres (P = 0.035 when delta-TL was studied as a continuous variable and P = 0.047 when categorized by the median). Moreover, patients carrying long telomeres also achieved major molecular response significantly earlier (P = 0.012). This study provides proof of concept that TL has a role in CML biology and when measured at diagnosis of CP-CML could help to identify patients likely to achieve DMR to first-line imatinib treatment.Natalia EstradaBlanca XicoyFabian BeierOlga GarciaCristian MoralesConcepción BoquéMiguel SagüésMónica S. Ventura FerreiraRolando VallansotSílvia MarcéMarta CabezónTim H. BrümmendorfLurdes ZamoraWolters KluwerarticleDiseases of the blood and blood-forming organsRC633-647.5ENHemaSphere, Vol 5, Iss 12, p e657 (2021)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the blood and blood-forming organs
RC633-647.5
spellingShingle Diseases of the blood and blood-forming organs
RC633-647.5
Natalia Estrada
Blanca Xicoy
Fabian Beier
Olga Garcia
Cristian Morales
Concepción Boqué
Miguel Sagüés
Mónica S. Ventura Ferreira
Rolando Vallansot
Sílvia Marcé
Marta Cabezón
Tim H. Brümmendorf
Lurdes Zamora
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
description Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation approaches. Few biological factors at diagnosis have been associated with this level of response. Telomere length (TL) in peripheral blood cells of patients with CML has been related to disease stage, response to therapy and disease progression, but little is known about its role on DMR. In this study, we analyzed if age-adjusted TL (referred as “delta-TL”) at diagnosis of chronic phase (CP)-CML might correlate with the achievement of DMR under first-line imatinib treatment. TL from 96 CP-CML patients had been retrospectively analyzed at diagnosis by monochrome multiplex quantitative PCR. We observed that patients with longer age-adjusted telomeres at diagnosis had higher probabilities to achieve DMR with imatinib than those with shortened telomeres (P = 0.035 when delta-TL was studied as a continuous variable and P = 0.047 when categorized by the median). Moreover, patients carrying long telomeres also achieved major molecular response significantly earlier (P = 0.012). This study provides proof of concept that TL has a role in CML biology and when measured at diagnosis of CP-CML could help to identify patients likely to achieve DMR to first-line imatinib treatment.
format article
author Natalia Estrada
Blanca Xicoy
Fabian Beier
Olga Garcia
Cristian Morales
Concepción Boqué
Miguel Sagüés
Mónica S. Ventura Ferreira
Rolando Vallansot
Sílvia Marcé
Marta Cabezón
Tim H. Brümmendorf
Lurdes Zamora
author_facet Natalia Estrada
Blanca Xicoy
Fabian Beier
Olga Garcia
Cristian Morales
Concepción Boqué
Miguel Sagüés
Mónica S. Ventura Ferreira
Rolando Vallansot
Sílvia Marcé
Marta Cabezón
Tim H. Brümmendorf
Lurdes Zamora
author_sort Natalia Estrada
title Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
title_short Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
title_full Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
title_fullStr Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
title_full_unstemmed Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
title_sort influence of telomere length on the achievement of deep molecular response with imatinib in chronic myeloid leukemia patients
publisher Wolters Kluwer
publishDate 2021
url https://doaj.org/article/eed0d7528f1d408cb71f85ec9f094861
work_keys_str_mv AT nataliaestrada influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT blancaxicoy influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT fabianbeier influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT olgagarcia influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT cristianmorales influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT concepcionboque influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT miguelsagues influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT monicasventuraferreira influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT rolandovallansot influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT silviamarce influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT martacabezon influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT timhbrummendorf influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
AT lurdeszamora influenceoftelomerelengthontheachievementofdeepmolecularresponsewithimatinibinchronicmyeloidleukemiapatients
_version_ 1718413592124981248